Zenotech Lab.

Why is Zenotech Laboratories Ltd falling/rising?

As of 31-Aug, Zenotech Laboratories Ltd's stock price is at 46.25, down 1.47%. Despite this decline, the stock has shown positive short-term trends and increased investor interest, suggesting potential for recovery.

As of 31-Aug, Zenotech Laboratories Ltd's stock price is currently at 46.25, reflecting a decrease of 0.69, or 1.47%. Despite this decline, the stock has shown some positive trends in recent performance metrics. Over the past week, Zenotech's stock has increased by 1.65%, outperforming the Sensex, which fell by 0.53%. Additionally, in the past month, the stock has risen by 3.84%, while the Sensex has decreased by 1.46%. <BR><BR>However, the year-to-date performance shows a slight increase of 0.13% for Zenotech, contrasting with a significant decline of 9.70% in the Sensex. Over the past year, Zenotech's stock has decreased by 17.03%, while the Sensex has only fallen by 3.57%. The longer-term view is less favorable, with a 3-year decline of 14.68% compared to an 18.70% increase in the Sensex, and a 5-year decline of 15.06% against a 33.72% rise in the benchmark.<BR><BR>Today's performance indicates that Zenotech has underperformed its sector by 2.19%. However, it is noteworthy that the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally upward trend in the short to medium term. Furthermore, there has been a significant increase in investor participation, with delivery volume rising by 407.66% compared to the 5-day average.<BR><BR>In summary, while Zenotech Laboratories Ltd is currently experiencing a price decline, it has shown positive short-term performance and increased investor interest, which may indicate potential for recovery despite its recent drop.

Who are in the management team of Zenotech Lab.?

The management team of Zenotech Lab includes Kavita Shah, Jignesh Anantray Goradia, Azadar Hussain Khan, Chintan Jitendra Shah, Abdul Gafoor Mohammad, Jagruti Prashant Sheth, and Rakeshchandra Jagdishprasad Sinha, serving in various roles such as Independent and Non-Executive Directors, and Company Secretary.

The management team of Zenotech Lab includes the following members:<BR><BR>1. Kavita Shah - Independent Director<BR>2. Jignesh Anantray Goradia - Non Executive Director<BR>3. Azadar Hussain Khan - Non Executive Director<BR>4. Chintan Jitendra Shah - Independent Director<BR>5. Abdul Gafoor Mohammad - Company Secretary & Compliance Officer<BR>6. Jagruti Prashant Sheth - Independent Director<BR>7. Rakeshchandra Jagdishprasad Sinha - Non Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Zenotech Lab. do?

Zenotech Laboratories Ltd is a micro-cap pharmaceutical company specializing in generic injectables, incorporated in 1989. As of June 2026, it reported net sales of 10 Cr and a market cap of INR 289 Cr.

Overview:<BR>Zenotech Laboratories Ltd is a pharmaceutical specialty generic injectables company operating in the Pharmaceuticals & Biotechnology industry within the micro-cap market segment.<BR><BR>History:<BR>Zenotech Laboratories Limited was incorporated in June 1989 and changed its name from Sunline Technologies Limited to its current name on August 9, 2004. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 10 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 289 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.32 <BR>Return on Equity: -2.52% <BR>Price to Book: 3.00<BR><BR>Contact Details:<BR>Address: S No 250-252 Turkapally Village, Shameerpet Mandal RR District Hyderabad Telangana: 500078 <BR>Tel: 91-40-23480430/0435 <BR>Email: abdul.gafoor@zenotech.co.in <BR>Website: http://www.zenotechlab.com

Who are the peers of the Zenotech Lab.?

Zenotech Lab.'s peers include Medicamen Biotec, Gennex Lab., BDH Industries, Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., and Kerala Ayurveda. BDH Industries shows the highest 1-year return at 54.17%, while Zenotech Lab. has a return of -17.03%.

Peers: The peers of Zenotech Lab. are Medicamen Biotec, Gennex Lab., BDH Industries, Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries, while Average management risk is found at Medicamen Biotec, Gennex Lab., Astonea Labs, Zenotech Lab., Everest Organics, Lyka Labs, and Nectar Lifesci., and the rest have Below Average management risk. Growth is Excellent at Gennex Lab., Good at Astonea Labs, and Below Average at Medicamen Biotec, Zenotech Lab., Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., and the rest. Capital Structure is Excellent at BDH Industries and Zenotech Lab., Good at Medicamen Biotec, Below Average at Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 54.17%, while the peer with the lowest is Kerala Ayurveda at -63.87%, with Zenotech Lab. having a 1-year return of -17.03%, which is better than Kerala Ayurveda but worse than BDH Industries. Additionally, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., and Kerala Ayurveda have negative six-month returns.

How big is Zenotech Lab.?

Summary could not be generated.

As of 31st August, Zenotech Laboratories Ltd has a market capitalization of 289.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Zenotech Laboratories Ltd reported net sales of 40.53 Cr. However, the company experienced a loss of 2.52 Cr in net profit during the same period.<BR><BR>The balance sheet data is unavailable for the latest annual period, so specific values for Shareholder's Funds and Total Assets cannot be provided.

Which are the latest news on Zenotech Lab.?

Are Zenotech Laboratories Ltd latest results good or bad?

Zenotech Laboratories Ltd's latest results are concerning, showing a net loss of ₹0.46 crore compared to a profit last year, despite a revenue growth of 11.11%. The significant drop in operating margins and negative return on equity indicate serious operational challenges, suggesting investors should be cautious.

Zenotech Laboratories Ltd's latest results indicate a challenging situation for the company. In Q1 FY27, Zenotech reported a net loss of ₹0.46 crore, a significant decline from a profit of ₹0.99 crore in the same quarter last year. This marks a troubling shift into negative profitability.<BR><BR>While the company did achieve an 11.11% year-on-year revenue growth, bringing net sales to ₹9.60 crore, this positive aspect is overshadowed by a drastic collapse in operating margins. The operating margin fell to 9.06%, down from 28.47% a year ago, highlighting severe operational inefficiencies and rising costs, particularly in employee expenses, which surged by nearly 39% year-on-year.<BR><BR>Additionally, the return on equity (ROE) has turned negative at -0.99%, indicating that the company is currently destroying shareholder value rather than generating returns. The stock has also underperformed significantly, declining 27.58% over the past year, contrasting sharply with the broader pharmaceutical sector's growth.<BR><BR>Overall, the results reflect a profitability crisis, with multiple red flags regarding operational efficiency and market confidence. Investors may want to approach Zenotech with caution until there are clear signs of a turnaround.

When is the next results date for Zenotech Laboratories Ltd?

The next results date for Zenotech Laboratories Ltd is 28 July 2026.

The next results date for Zenotech Laboratories Ltd is scheduled for 28 July 2026.

Should I buy, sell or hold Zenotech Laboratories Ltd?

How has been the historical performance of Zenotech Lab.?

Zenotech Lab has experienced declining net sales and increasing losses from 2008 to 2010, with net sales dropping from 8.24 Cr to 6.57 Cr. However, there are signs of improvement in cash management, as cash and cash equivalents rose significantly during the same period.

Answer:<BR>The historical performance of Zenotech Lab shows a trend of declining net sales and increasing losses over the years reported.<BR><BR>Breakdown:<BR>Zenotech Lab's net sales decreased from 8.24 Cr in March 2008 to 6.57 Cr in March 2010, with a slight increase from 6.02 Cr in March 2009. The total operating income mirrored this trend, remaining at 6.57 Cr in March 2010, down from 8.24 Cr in March 2008. The total expenditure, excluding depreciation, also declined from 18.12 Cr in March 2008 to 16.01 Cr in March 2010. However, the operating profit (PBDIT) remained negative, improving slightly from -9.88 Cr in March 2008 to -7.33 Cr in March 2010. The profit before tax showed a similar pattern, with losses narrowing from -13.54 Cr in March 2008 to -12.54 Cr in March 2010. The profit after tax also reflected this negative trend, with losses of -15.89 Cr in March 2008, -17.56 Cr in March 2009, and -12.53 Cr in March 2010. The earnings per share improved from -4.39 in March 2008 to -3.45 in March 2010. Cash flow from operating activities remained negative, although it improved from -15.54 Cr in March 2009 to -9.85 Cr in March 2010. The closing cash and cash equivalents increased significantly from 0.60 Cr in March 2008 to 12.33 Cr in March 2010, indicating a positive cash flow from investing activities. Overall, Zenotech Lab has faced challenges with profitability, but there are signs of improvement in cash management.

Who are the top shareholders of the Zenotech Lab.?

The top shareholders of Zenotech Lab are Sun Pharmaceutical Industries Limited with 68.84%, followed by Padmasree Chigurupati at 5.26%, and individual investors holding 22.78%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Zenotech Lab include Sun Pharmaceutical Industries Limited, which holds a significant majority stake of 68.84%. The highest public shareholder is Padmasree Chigurupati, with a holding of 5.26%. Additionally, individual investors collectively hold 22.78% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Zenotech Lab.

Is Zenotech Lab. overvalued or undervalued?

Zenotech Lab. is currently considered very expensive and overvalued due to high valuation metrics and poor stock performance, making it a less compelling investment at its current price.

As of 13 August 2021, the valuation grade for Zenotech Lab. has moved from risky to very expensive. The company is currently overvalued based on its high valuation metrics, including a PE ratio of 86.06, an EV to EBIT ratio of 49.55, and an EV to EBITDA ratio of 25.21. These figures significantly exceed those of its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, indicating that Zenotech Lab. is trading at a premium compared to the industry.<BR><BR>In comparison to the broader market, Zenotech Lab.'s stock has underperformed year-to-date with a return of -11.95% against the Sensex's 5.63%. This trend reinforces the conclusion that the stock is overvalued, as investors may be paying a high price for earnings that do not justify such a valuation. Overall, the combination of elevated ratios and poor relative performance suggests that Zenotech Lab. is not a compelling investment at its current price.

What is the technical trend for Zenotech Lab.?

As of May 12, 2025, Zenotech Lab's technical trend is mildly bearish, with mixed signals from MACD, Bollinger Bands, and moving averages across different time frames.

As of 12 May 2025, the technical trend for Zenotech Lab has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands show a mildly bullish trend on the weekly chart but are bearish on the monthly, further contributing to the overall mildly bearish outlook. Daily moving averages are also mildly bearish, reinforcing the current trend. The KST is mildly bullish on the weekly but mildly bearish on the monthly, indicating some short-term strength that is not reflected in the longer term. Overall, the current technical stance is mildly bearish, with key indicators showing mixed signals across different time frames.

Has Zenotech Lab. declared dividend?

No Dividend History Available